Sai Parenteral’s IPO – Review

About the Company

Sai Parenteral’s Ltd. is a diversified pharmaceutical formulations company engaged in research, development and manufacturing across multiple therapeutic segments. The company operates in two key verticals — branded generic formulations and CDMO (Contract Development and Manufacturing Organisation) services.

Its product portfolio spans cardiovascular, anti-diabetic, neuropsychiatry, respiratory, antibiotics, gastroenterology and dermatology segments, covering a wide range of dosage forms including injectables, tablets, capsules and liquid orals. The company operates five manufacturing facilities, including WHO-GMP, PIC/S and TGA-accredited units, enabling access to regulated and semi-regulated markets.

Sai Parenteral’s entered export markets in FY23 and has expanded presence across Australia, New Zealand, Southeast Asia, Middle East and Africa. Its strong focus on CDMO services provides a scalable long-term growth opportunity, supported by global outsourcing trends.

The company’s diversified product portfolio, regulatory-compliant infrastructure and growing export footprint position it as an emerging player in the pharma manufacturing ecosystem.

Financials and Key Parameters

Financial Performance (Rs. Crore)

Key Ratios

Peer Comparison

The company operates in the pharmaceutical formulations and CDMO segment, competing with mid-sized pharma companies and contract manufacturing players.

• EBITDA margins (~18–24%) are relatively strong for its size
• Return ratios show inconsistency, indicating evolving scale
• Debt levels have reduced significantly, improving financial stability
• CDMO focus provides higher scalability compared to pure generics

👉 Inference: Growing pharma player with improving balance sheet, but still behind established listed peers in scale and consistency

Industry Scenario

The pharmaceutical industry in India continues to benefit from strong global demand for generics and increasing outsourcing through CDMO models.

India is a preferred manufacturing hub due to cost advantage, regulatory capabilities and skilled workforce. CDMO players are witnessing strong traction as global pharma companies outsource manufacturing.

However, the industry remains highly regulated, with risks related to compliance, pricing pressure and export dependency.

👉 Outlook: Strong structural growth driven by exports and CDMO, but regulatory risks remain key

Valuation Analysis

• Price: Rs. 392
• EPS (FY25): Rs. 5.43
• P/E: ~72x

👉 Valuation appears expensive considering:
• Small scale of operations
• Moderate return ratios consistency
• High growth expectations already priced in

👉 Oversubscription Outlook:
• Retail: Moderate
• HNI: Limited interest likely
• QIB: Highly valuation sensitive

👉 Key Trigger: Institutional participation + subscription momentum

Chanakya Verdict

Sai Parenteral’s offers exposure to a growing pharma player with strong CDMO focus and expanding export presence. Improving profitability and reducing debt are positive indicators for the business.

However, steep valuation (~72x P/E), relatively small scale and regulatory risks remain key concerns.

👉 Final View:
• Strong growth opportunity via CDMO
• Valuation is the biggest concern
• Not a straightforward investment case

🧠 Chanakya Verdict Block

Investment Call: ⚠️ Avoid / Apply only at discretion

Risk Meter:
🟡🟡🟡🟡⚪ (Moderately High Risk)

Valuation Meter:
🔴🔴🔴🔴⚪ (Expensive Valuation)

Listing Expectation:
🟡⚪⚪⚪⚪ (Low – GMP neutral)

Final Verdict

👉 Avoid for listing gains due to expensive valuation
👉 Long-term investors may track post-listing corrections
👉 Watch institutional participation before any decision